Clinical Trials Directory

Trials / Completed

CompletedNCT02182492

Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery

Comparison of Different Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
187 (actual)
Sponsor
Zheng Liu · Academic / Other
Sex
All
Age
16 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Endoscopic sinus surgery (ESS) is widely considered to be the gold standard in the surgical management of chronic rhinosinusitis (CRS) that has failed maximal medical therapy. Nevertheless, the postoperation medical therapy was considered as a crucial procedure for the success of ESS. Both glucocorticoids and macrolide antibiotics have been recommended for the treatment of CRS, but their effect as postoperation medical therapies of ESS need more clinical data to clarify. The purpose of this prospective, randomized,study is to determine the effect of glucocorticoids and macrolide antibiotics for the postoperation medical therapy of ESS in different subtypes of CRS.

Detailed description

Chronic rhinosinusitis (CRS) is a multifactorial inflammatory disorder that causes various symptoms including nasal obstruction, rhinorrhea, olfactory dysfunction, facial pain, and headache . Endoscopic sinus surgery (ESS) is usually recommended for patients who do not response well to conservative treatments. Although surgery is effective to alleviate symptoms and improve the quality of life of CRS patients, a followed long-term postoperative medical treatment is indispensable. Current European and American guidelines recommend glucocorticoids and antibiotics as the primary pharmacotherapeutic approaches for CRS before and after ESS. However, there are a number of CRS patients not responding well to glucocorticoid treatment and conflicting results exist regarding the efficacy of long-term, low-dose macrolide treatment. One potential reason is that CRS is a heterogeneous group of disorders unified by similar clinical presentations and its phenotypes and/or endotypes may be important factors determining the efficacy of treatments.

Conditions

Interventions

TypeNameDescription
DRUGClarithromycinClarithromycin 250 mg tablet once daily for 3 months
DRUGGlucocorticoidFluticasone propionate nasal spray 200 μg/d for 3 months

Timeline

Start date
2014-01-01
Primary completion
2015-12-01
Completion
2016-06-01
First posted
2014-07-08
Last updated
2018-09-25
Results posted
2018-09-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02182492. Inclusion in this directory is not an endorsement.